Kansikuva näyttelystä LabReflex

LabReflex

Podcast by Christopher Zahner, MD

englanti

Teknologia & tieteet

Rajoitettu tarjous

3 kuukautta hintaan 7,99 €

Sitten 7,99 € / kuukausiPeru milloin tahansa.

  • Podimon podcastit
  • Lataa offline-käyttöön
Aloita nyt

Lisää LabReflex

A conversational podcast about more innovative diagnostics, lab insights, and the future of clinical testing. Hosted by Dr. Christopher Zahner, LabReflex brings expert voices, industry trends, and practical conversations straight from the laboratory bench to your brain.

Kaikki jaksot

27 jaksot

jakson Pulse: Who Controls the Diagnostic Front Door? kansikuva

Pulse: Who Controls the Diagnostic Front Door?

This week on LabReflex Pulse, Dr. Chris Zahner and Dr. Aakash Bhatia dive into a series of stories that all point toward a bigger shift happening inside laboratory medicine: diagnostics are becoming infrastructure. From Nebraska rapidly validating an Andes virus PCR assay during a hantavirus scare… to Epic and Labcorp deepening diagnostic workflow integration… to AI pathology consolidation and real-time infectious disease surveillance dashboards — the organizations controlling diagnostic workflows may increasingly shape the future of healthcare itself. This week’s topics: Nebraska’s rapid Andes virus PCR response Following a hantavirus outbreak aboard the MV Hondius cruise ship, the Nebraska Public Health Laboratory rapidly validated an Andes virus PCR assay before exposed passengers arrived in the United States. The story raises major questions about rare-pathogen preparedness and rapid assay deployment in the post-COVID era. WIRED coverage: https://www.wired.com/story/race-to-develop-andes-hantavirus-test/ [https://www.wired.com/story/race-to-develop-andes-hantavirus-test/] CDC Health Alert: https://www.cdc.gov/han/php/notices/han00528.html [https://www.cdc.gov/han/php/notices/han00528.html] WHO outbreak notice: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON600 [https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON600] Epic + Labcorp integration: interoperability or market positioning? Labcorp announced expanded integration with Epic Aura, giving Epic users broader access to Labcorp’s testing menu and specialty diagnostics workflows. Chris and Aakash discuss whether EHR workflow design may increasingly influence diagnostic utilization — and whether hospital outreach laboratories should be paying closer attention. Labcorp announcement: https://ir.labcorp.com/news-releases/news-release-details/labcorp-and-epic-expand-collaboration-advance-diagnostic [https://ir.labcorp.com/news-releases/news-release-details/labcorp-and-epic-expand-collaboration-advance-diagnostic] ARUP launches infectious disease positivity dashboard ARUP introduced a national infectious disease positivity trends dashboard using deidentified laboratory data to help identify emerging patterns and seasonal shifts. The episode explores whether large reference laboratories are quietly becoming real-time public health surveillance networks. ARUP announcement: https://www.aruplab.com/news/05-13-2026/arup-launches-national-infectious-disease-test-positivity-trends [https://www.aruplab.com/news/05-13-2026/arup-launches-national-infectious-disease-test-positivity-trends] Roche acquires PathAI Roche announced plans to acquire digital pathology company PathAI in a major move signaling that AI pathology is transitioning from experimental technology to enterprise infrastructure. Roche announcement: https://www.roche.com/media/releases/med-cor-2026-05-07 [https://www.roche.com/media/releases/med-cor-2026-05-07] Reuters coverage: https://www.reuters.com/legal/litigation/switzerlands-roche-agrees-acquire-us-based-pathai-2026-05-07/ [https://www.reuters.com/legal/litigation/switzerlands-roche-agrees-acquire-us-based-pathai-2026-05-07/] Quick Hit: Cepheid Xpert GI Panel Cepheid received IVDR CE marking for its multiplex GI PCR panel, capable of detecting 11 gastrointestinal pathogens in approximately 75 minutes. The conversation touches on the continued expansion of rapid syndromic molecular testing and what it may mean for the future of microbiology workflows. FDA summary: https://www.accessdata.fda.gov/cdrh_docs/reviews/K251721.pdf [https://www.accessdata.fda.gov/cdrh_docs/reviews/K251721.pdf] Cepheid announcement: https://www.morningstar.com/news/pr-newswire/20260513la58308/cepheid-receives-ce-marking-under-ivdr-for-xpert-gi-panel [https://www.morningstar.com/news/pr-newswire/20260513la58308/cepheid-receives-ce-marking-under-ivdr-for-xpert-gi-panel] Subscribe to LabReflex! For more conversations at the intersection of laboratory medicine, diagnostics, pathology, and healthcare strategy, subscribe wherever you get your podcasts.

19. touko 2026 - 36 min
jakson Deep Dive: Your Quality Plan Is Not Your Quality System kansikuva

Deep Dive: Your Quality Plan Is Not Your Quality System

Your Quality Plan Is Not Your Quality System In this LabReflex deep dive, we break down a simple but important inspection-readiness idea: A quality plan is what the lab says it does. A quality system is what actually happens when something goes wrong. Many labs prepare for inspection by trying to show that failures never happen. But real quality is not about pretending the lab is perfect. It is about having a consistent, repeatable system for detecting problems, documenting them, reviewing them, correcting them, verifying the fix, and improving over time. Key framework Detect → Document → Review → Correct → Verify → Improve A strong quality system makes follow-up obvious. It helps the lab answer: *  How did we know there was a problem?  *  Where was it documented?  *  Who reviewed it?  *  What changed?  *  Did the fix work?  *  What improved because of it?  Main example We use critical value notification delays as an example. A weak response is: “Staff were reminded.” A stronger response asks: *  Why were the calls delayed?  *  Was there a shift-specific pattern?  *  Were contact numbers correct?  *  Was the escalation process clear?  *  Did the lab audit afterward to prove improvement?  Big takeaway The strongest labs are not the ones that claim they never have problems. They are the ones that can show their quality system in action. The goal is not perfection. The goal is control, learning, and consistent improvement.

13. touko 2026 - 27 min
jakson Pre-Inspection Prep: Why Most Labs Prepare the Wrong Way kansikuva

Pre-Inspection Prep: Why Most Labs Prepare the Wrong Way

Most labs do not prepare poorly because they do not care. They prepare poorly because they prepare for the wrong thing. Instead of stress-testing how the lab actually functions, they often review policies, clean things up, and make sure staff can answer a few familiar questions. The problem is that inspectors are usually not looking for memorization. They are trying to figure out whether the system is real. Does the work actually happen the way the lab says it happens? Do staff know what to do when something goes wrong? Can the lab prove it? In this episode, we focus on three deceptively simple inspection questions that reveal far more than factual knowledge: What do you do when QC fails? How do you know this instrument is working correctly? What do you do with an unexpected result? These are not trivia questions. They are system questions. They test error handling, escalation, judgment, consistency, and whether the lab’s workflow and documentation actually match what leadership believes is happening. We also lay out a practical framework for running a more useful mock inspection. Instead of asking staff to repeat policy language, we argue that labs should build scenario-based exercises around real-world stress points. The goal is to test whether staff can explain what they would do, show how they would do it, and trace their answer back to actual records, logs, documentation, and escalation pathways. That is where the real weaknesses usually show up. A major theme in the conversation is that most labs do not have a pure knowledge problem. They have an alignment problem. One person gives one answer, another gives a slightly different one, and the exception pathway is often much less solid than leaders assume. That is exactly the kind of thing inspectors notice quickly. A lab may look fine on the surface and still be vulnerable if its people, workflow, and documentation do not line up under pressure. In the episode, we walk through a five-part framework for better pre-inspection prep: testing scenarios instead of memory, making staff show and not just tell, tracing every answer back to evidence, stress-testing the highest-value inspection questions, and scoring alignment rather than just correctness. The underlying point is simple: if you want to know whether your lab is actually ready, you have to simulate the moments when trust in the system is challenged. In this episode, we discuss: *  Why most mock inspections are too soft to be useful  *  What inspectors are really testing when they question frontline staff  *  Why QC failure, instrument trust, and unexpected results are such revealing scenarios  *  How to move from fact-recall exercises to scenario-based system testing  *  Why demonstration and documentation matter as much as verbal answers  *  How to score inspection readiness in a more realistic way  *  Why consistency across staff may be the most important signal of all  Key takeaway: If a lab wants to truly prepare for inspection, it should stop treating readiness like a quiz and start treating it like a system check. The real test is not whether one person can give a polished answer. It is whether the lab can respond consistently, correctly, and visibly when something does not go according to plan.

4. touko 2026 - 26 min
jakson Financial Pressure, Volume Signals, and the Future of Phlebotomy kansikuva

Financial Pressure, Volume Signals, and the Future of Phlebotomy

This week, we focused on the financial and operational signals coming out of the lab industry. Quest Diagnostics reported strong first-quarter results and raised its full-year guidance, suggesting routine testing demand may be holding up better than expected. At the same time, revenue per requisition was down, which is a useful reminder that higher volume does not automatically mean easier economics. Thermo Fisher also posted a strong quarter, but with a more cautious tone underneath, noting that academic and government demand still has not fully normalized. Together, those results paint a mixed picture: activity may be there, but the broader lab ecosystem still looks uneven. We also discussed CAP’s new survey data showing that reimbursement pressure is no longer just a budget issue. CAP reported that 71 percent of practices experienced negative effects from decreased reimbursement over the past two years, with some practices reporting increased turnaround time, reduced laboratory staffing, and reduced pathologist staffing. That makes the conversation more concrete. This is no longer just about payment policy in the abstract. It is about what kind of service model labs can realistically sustain when the financial pressure continues to build. From there, we looked at the broader billing environment, including denials, downcoding, and prior authorization burden. CAP TODAY’s recent billing discussion made the point that pathology groups are being pressured from multiple angles at once. The problem is not just lower reimbursement. It is also the growing amount of administrative work attached to revenue collection. Labs are increasingly having to spend more time and effort fighting for payment on work they already performed. We closed with one of the more unusual stories of the week: robotic phlebotomy. CAP TODAY reported that Vitestro raised $70 million to advance its autonomous robotic phlebotomy platform, with funding aimed at development, manufacturing scale-up, clinical expansion, and commercial readiness. On the surface, it sounds futuristic. But the more interesting question is why serious investors and health systems are paying attention. If labor shortages and workflow friction at the blood-draw step are painful enough, automation starts to look less like a gimmick and more like a real operational bet. In this episode, we discuss: *  What Quest’s quarter may be telling us about routine diagnostic demand  *  Why Thermo Fisher’s results suggest the broader lab market is still uneven  *  How reimbursement cuts are now showing up in staffing and turnaround time  *  Why billing friction is becoming part of the operational burden on labs  *  Whether robotic phlebotomy is a novelty story or an early sign of where workforce pressure is headed  Key takeaway: Labs may be busy, but that does not mean they are financially comfortable. This week’s stories suggest a field that is active, pressured, and still adapting with demand holding up in some places, strain deepening in others, and automation continuing to push into new corners of laboratory medicine.

27. huhti 2026 - 25 min
Loistava design ja vihdoin on helppo löytää podcasteja, joista oikeasti tykkää
Loistava design ja vihdoin on helppo löytää podcasteja, joista oikeasti tykkää
Kiva sovellus podcastien kuunteluun, ja sisältö on monipuolista ja kiinnostavaa
Todella kiva äppi, helppo käyttää ja paljon podcasteja, joita en tiennyt ennestään.

Valitse tilauksesi

Suosituimmat

Rajoitettu tarjous

Premium

  • Podimon podcastit

  • Ei mainoksia Podimon podcasteissa

  • Peru milloin tahansa

3 kuukautta hintaan 7,99 €
Sitten 7,99 € / kuukausi

Aloita nyt

Premium

20 tuntia äänikirjoja

  • Podimon podcastit

  • Ei mainoksia Podimon podcasteissa

  • Peru milloin tahansa

30 vrk ilmainen kokeilu
Sitten 9,99 € / kuukausi

Aloita maksutta

Premium

100 tuntia äänikirjoja

  • Podimon podcastit

  • Ei mainoksia Podimon podcasteissa

  • Peru milloin tahansa

30 vrk ilmainen kokeilu
Sitten 19,99 € / kuukausi

Aloita maksutta

Vain Podimossa

Suosittuja äänikirjoja

Aloita nyt

3 kuukautta hintaan 7,99 €. Sitten 7,99 € / kuukausi. Peru milloin tahansa.